ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Dopa responsive dystonia due to a GCH1 gene variant mimicking hereditary spastic paraparesis.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Follow-up and outcome of patients with primary BH4 deficiencies.Frontiers in neurologyPooled it
- Clinical Phenotype Comparison in Polish Patient Cohorts with and Without Molecular Diagnosis of Dystonia.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDopa-responsive dystonia (DRD) is a group of rare forms of genetically determined dystonia. Large improvements of symptoms can be seen with small doses of levodopa. As a treatable condition, it must be diagnosed and treated to improve the patients' functional outcome and quality of life. CASE PRESENTATION: We describe the case of a woman affected by progressive gait impairment and lower limb rigidity, started at the age of 15. For talipes equinovarus (clubfoot), she underwent Achilles tendon lengthening and anterior tibial haemitendon transposition surgery. Family history collection revealed that her mother had been diagnosed with spastic paraparesis in adolescence. Clinical phenotype and family history suggested a diagnosis of hereditary spastic paraparesis (HSP), supported by a mild involvement of the pyramidal tract in lower limbs at the motor evoked potential. Clinical evaluation revealed the presence of mild signs of dystonia, as a foot and cervical dystonia and upper limbs dystonic tremor. Indeed, a virtual panel for dystonia genes showed a pathogenic splice-site variant in GCH1. The patient was diagnosed with DRD and low doses of levodopa were started with clinical improvement of both gait and dystonia.
conclusionWe describe the clinical history of a patient with dopa responsive dystonia, which was initially diagnosed with HSP. Misdiagnosis can result in a significant delay in diagnosis and treatment initiation, so it is of the utmost importance to identify these patients without delay, looking for the presence of soft dystonia signs and performing an empirical trial with low doses of levodopa.
Indexed as
Identifiers
40140190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.